Is restoration of intracellular trafficking clinically feasible in the long QT syndrome?: The example of HERG mutations

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 3, 2003, Pages 320-322

  Kaufman, Elizabeth S ^a   Ficker, Eckhard ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 4 PHENYLBUTYRIC ACID; ASTEMIZOLE; CISAPRIDE; POTASSIUM CHANNEL; THAPSIGARGIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; CHANNEL GATING; GENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HEART REPOLARIZATION; HERG GENE; INTRACELLULAR TRANSPORT; LONG QT SYNDROME; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN PROCESSING; REVIEW; TEMPERATURE DEPENDENCE; TEMPERATURE SENSITIVITY; TRANSCRIPTION REGULATION;

EID: 0037359570     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2003.02363.x     Document Type: Review

References (18)

1. Moss AJ, Schwartz PJ, Crampton RS, et al: The long-QT syndrome: Prospective longitudinal study of 328 families. Circulation 1991;84:1136-1144.
2. Keating MT, Sanguinetti MC: Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-580.
3. Zareba W, Moss AJ, Schwartz PJ, et al: Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998;339:960-965.
4. Moss AJ, Zareba W, Kaufman ES, et al: Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002;105:794-799.
5. Chen J, Zou A, Splawski I, et al: Long-QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. J Biol Chem 1999;274:10113-10118.
6. Furutani M, Trudeau MC, Hagiwara N, Seki A, Gong O, Zhou Z, Imamura S, Nagashima H, Kasanuki H, Takao A, Momma K, January CT, Robertson GA, Matsuoka R: A novel mechanism associated with an inherited cardiac arrhythmia: Defective protein trafficking by the mutant HERG (G601S) channel. Circulation 1999;99:2290-2294.
7. Zhou Z, Gong Q, January CT: Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. J Biol Chem 1999;274:31123-31126.
8. Ficker E, Thomas D, Viswanathan PC, et al: Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. Am J Physiol Heart Circ Physiol 2000;279:H1748-H1756.
9. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992:358:761-764.
10. Smith DF, Whitesell L, Katsanis E: Molecular chaperones: Biology and prospects for pharmacological intervention. Pharmacol Rev 1998;50:493-513.
11. Fischer H, Fukuda N, Barbry P, Illek B, Sartori C, Matthay MA: Partial restoration of defective chloride conductance in ΔF508 CF mice by trimethylamine oxide. Am J Physiol Lung Cell Mol Physiol 2001:281:L52-L57.
12. Ficker E, Obejero-Paz CA, Zhao S, Brown AM: The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-go-go-related gene (HERG) mutations. J Biol Chem 2002;277:8912-8919.
13. Rajamani S, Anderson CL, Anson BD, January CT: Pharmacological rescue of human K channel long-QT2 mutations: Human ether-a-go-go-related gene rescue without block. Circulation 2002;105:r114-r119.
14. Egan ME, Glockner-Pagel J, Ambrose CA, Cahill PA, Pappoe L, Balamuth N, Cho E, Canny S, Wagner CA, Geibel J, Caplan MJ: Calcium-pump inhibitors induce functional surface expression of L protein in cystic fibrosis epithelial cells. Nat Med 2002;8:485-492.
15. Cheng SH, Fang SL, Zabner J, Marshall J, Piraino S, Schiavi SC, Jefferson DM, Welsh MJ, Smith AE: Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am J Physiol 1995;268:L615-L624.
16. Rubenstein RC, Egan ME, Zeitlin PL: In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997;100:2457-2465.
17. Rubenstein RC, Zeitlin PL: A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998:157:484-490.
18. Splawski, I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT: Spectrum of mutations in long-QT syndrome genes KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178-1185.